All In Biotech

Free tool

FAERS Monitor: Brukinsa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 218785 or its brand name (Brukinsa, Zanubrutinib). Reports on generic versions are filed under their own applications.

Reports

4,539

Serious

3,384

75% of reports

Hospitalization

1,174

Death reported

505

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use585
  • disease progression318
  • myelosuppression254
  • fatigue249
  • anaemia247
  • white blood cell count decreased247
  • contusion241
  • platelet count decreased219
  • rash212
  • death211
  • pneumonia201
  • diarrhoea185
  • nausea156
  • drug ineffective155
  • asthenia154

Reports by year received

View as table
YearReports
20181
201917
202089
2021152
2022437
2023733
2024926
20251,195
2026989

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,620 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
myelosuppressionSignal25432.929.27,783
disease progressionSignal31812.511.23,358
contusionSignal24111.610.32,335
white blood cell count decreasedSignal24710.69.42,139
platelet count decreasedSignal2199.58.41,670
anaemiaSignal2476.05.31,034
off label useSignal5853.12.9864
pneumoniaSignal2012.92.5248
rashSignal2122.32.0150
asthenia1541.91.666
fatigue2491.51.340
diarrhoea1851.31.215
death2111.11.03
nausea1560.90.81
drug ineffective1550.50.562

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.